such as
Alpha-1
antitrypsin. These deficiencies ultimately can lead to a dangerous accumulation of toxins and/or chronic damage that is often fatal if not
addressed by ongoing medical care and an organ transplant. Our therapeutic strategy is to create small implantable tissue patches, NovoTissues, which may one day postpone or obviate the need for a complete organ transplant. Our
first IND program will target
Alpha-1
antitrypsin deficiency. In December 2017, the FDA granted Organovo ODD for
Alpha-1
antitrypsin deficiency, which confers certain
regulatory access, streamlining, and financial benefits to our program. We expect to file our first IND by the end of calendar 2020, and we intend to develop additional IND track programs utilizing our NovoTissues to target other indications
within this disease category.
Corporate Information
We are operating the business of our subsidiaries, including Organovo, Inc., our wholly-owned subsidiary, which we acquired in February 2012.
Organovo, Inc. was incorporated in Delaware in April 2007. Our common stock has traded on the Nasdaq Global Market under the symbol ONVO since August 8, 2016. Prior to that time it traded on the NYSE MKT under the symbol
ONVO and prior to that was quoted on the OTC Market. Our wholly-owned subsidiary, Samsara Sciences, Inc., was incorporated in Delaware in December 2014. In September 2015, we established another wholly-owned subsidiary in the United
Kingdom, Organovo U.K., Ltd., for the primary purpose of establishing a sales presence in Europe.
Our principal executive offices are
located at 6275 Nancy Ridge Dr., San Diego, California 92121 and our phone number is (858)
224-1000.
Our Internet website can be found at http://www.organovo.com. The information found on our Internet website
is not part of this prospectus supplement.
The Securities We May Offer
We may offer up to $100,000,000 of common stock, preferred stock and warrants in one or more offerings and in any combination, including in
units from time to time. We may also offer common stock upon conversion of preferred stock, or common stock or preferred stock upon the exercise of warrants. This prospectus provides you with a general description of the securities we may offer. A
prospectus supplement, which we will provide each time we offer securities, will describe the specific amounts, prices and terms of these securities.
Common Stock
Each holder
of our common stock is entitled to one vote for each share on all matters to be voted upon by the stockholders, and there are no cumulative rights. Subject to any preferential rights of any outstanding preferred stock, holders of our common stock
are entitled to receive ratably the dividends, if any, as may be declared from time to time by the board of directors out of funds legally available therefor. If there is a liquidation, dissolution or winding up of our company, holders of our common
stock would be entitled to share in our assets remaining after the payment of liabilities and any preferential rights of any outstanding preferred stock. Our common stock is described in greater detail in this prospectus under Description of
Capital StockCommon Stock.
Preferred Stock
Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more
series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation
preferences, of each series of preferred stock.
Each series of preferred stock, if issued, will be more fully described in the particular
prospectus supplement that will accompany this prospectus, including redemption provisions, rights in the event of our liquidation,